FDA rejects psychedelic MDMA as treatment for PTSD

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on telegram
Share on email
Share on reddit
Share on whatsapp
Share on telegram


WASHINGTON — Federal health regulators on Friday refused to approve the psychedelic drug MDMA as a therapy for PTSD, a major setback for groups seeking a groundbreaking ruling in favor of using mind-altering substances to treat serious conditions. of mental health.

Drugmaker Lykos Therapeutics said the FDA notified the company that its drug “could not be approved based on the data presented to date” and requested an additional late-stage study. Such studies typically take several years and millions of dollars to conduct. The company said it plans to ask the agency to reconsider.

Lykos and other psychedelic companies hoped that MDMA would be approved and pave the way for other hallucinogenic drugs to enter the medical mainstream. If the FDA had granted the request, MDMA, also known as ecstasy or molly, would have become the first illegal psychedelic to become a federally approved medication.

The FDA’s decision was expected after a panel of government advisers voted overwhelmingly against the use of the drug for post-traumatic stress disorder in June. The negative vote came after an all-day meeting in which experts scrutinized the Lykos study data, research methods and the drug’s possible risks, including heart problems, injuries and abuse.

read more: Inside Ibogaine, One of the Most Promising and Dangerous Psychedelics for Addiction

The FDA said Friday that the MDMA application had “significant limitations” that “prevent the agency from concluding that the drug is safe and effective for the proposed indication.” The agency said it will continue to encourage “innovation in psychedelic treatments and other therapies to meet these medical needs.”

Lykos said the issues raised by the FDA in what is called a complete response letter echoed concerns during the June meeting.

“The FDA’s request for another study is deeply disappointing,” Lykos CEO Amy Emerson said Friday in a statement. “Our hearts break for the millions of military veterans, first responders, victims of sexual and domestic abuse, and countless others suffering from PTSD who may now face years more without access to new treatment options.”

Lykos is essentially a corporate spinoff of the country’s leading psychedelic advocacy group, the Multidisciplinary Association for Psychedelic Studies, or MAPS, which financed early MDMA studies by raising millions of dollars from wealthy backers.

The group has been a pioneer in investigating the medical use of psychedelic substances, which major pharmaceutical companies have been unwilling to fund. Two small studies submitted to the FDA suggested that combining MDMA with psychotherapy led to significant relief of PTSD symptoms.

read more: America has reached peak therapy. Why is our mental health getting worse?

Antidepressants are now the only FDA-approved medications for PTSD, which is closely linked to depression, anxiety and suicidal thinking and is more prevalent among women and veterans.

In recent years, research into MDMA has been widely publicized by combat veterans, who say a lack of treatment options for the disease has contributed to higher suicide rates among military personnel. Last month, veterans who support psychedelic therapy rallied at the Capitol in support of the drug. And more than 80 House and Senate lawmakers have signed letters to the FDA in recent weeks calling for MDMA’s approval.

But the FDA review brought new scrutiny to the investigation. The vast majority of patients in the Lykos studies correctly guessed whether they had received MDMA or a dummy pill, making it “nearly impossible” to maintain “blinding,” which is considered essential to medical research, according to FDA internal officials.

In recent months, separate allegations of misconduct have emerged, including that some investigators involved in the studies coached patients to suppress negative results or inflate positive ones.

Despite the setback, many experts say other psychedelics may fare better before the agency.

MDMA is the first in a series of psychedelic substances expected to be reviewed by the FDA in the coming years as part of a resurgence of interest in their therapeutic potential.

The idea of ​​using psychedelics to enhance psychotherapy is not new. Some therapists in California used MDMA during the 1970s and 1980s — when it was still legal — to facilitate couples therapy sessions. MAPS was founded in 1986 to oppose a federal ruling that placed MDMA in the same ultra-restrictive drug category as heroin, LSD and other illegal psychedelics.

MAPS studies on MDMA began more than a decade ago. Since then, dozens of small pharmaceutical startups have entered the field, studying other substances like psilocybin and LSD for conditions like depression, addiction and anxiety. These studies are generally larger and more rigorous than the MDMA studies submitted to the FDA.

Two drug developers, Compass Pathways and Usona Institute, are conducting late-stage studies of psilocybin – the active ingredient in magic mushrooms – for severe depression.



This story originally appeared on Time.com read the full story

Support fearless, independent journalism

We are not owned by a billionaire or shareholders – our readers support us. Donate any amount over $2. BNC Global Media Group is a global news organization that delivers fearless investigative journalism to discerning readers like you! Help us to continue publishing daily.

Support us just once

We accept support of any size, at any time – you name it for $2 or more.

Related

More

1 2 3 9,595

Don't Miss

Apple launches Final Cut Camera app to support multi-camera productions

Apple launches Final Cut Camera app to support multi-camera productions

Apple is launching a new Final Cut Camera app for
University of Florida President Ben Sasse will step down, citing wife’s health

University of Florida President Ben Sasse will step down, citing wife’s health

University of Florida President and former Nebraska Sen. Ben Sasse